摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-溴-2-甲氧基-5-硝基吡啶 | 15862-50-7

中文名称
3-溴-2-甲氧基-5-硝基吡啶
中文别名
2-甲氧基-3-溴-5-硝基吡啶
英文名称
3-bromo-2-methoxy-5-nitropyridine
英文别名
——
3-溴-2-甲氧基-5-硝基吡啶化学式
CAS
15862-50-7
化学式
C6H5BrN2O3
mdl
——
分子量
233.021
InChiKey
VRCSBPXFYAADHQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    89°C
  • 沸点:
    285.0±35.0 °C(Predicted)
  • 密度:
    1.730±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    67.9
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 危险等级:
    IRRITANT
  • 危险品标志:
    Xi
  • 海关编码:
    2933399090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    室温,惰性气体

SDS

SDS:4a814540465762878deb236980855dd0
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-Bromo-2-methoxy-5-nitropyridine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 3-Bromo-2-methoxy-5-nitropyridine
CAS number: 15862-50-7

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H5BrN2O3
Molecular weight: 233.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-溴-2-甲氧基-5-硝基吡啶盐酸正丁基锂硫酸铁粉potassium carbonate 、 sodium nitrite 作用下, 以 四氢呋喃乙醇正己烷N,N-二甲基甲酰胺 为溶剂, 反应 10.0h, 生成 4-chloro-2-({2,5-dimethoxypyrid-3-yl}carbonyl)aniline
    参考文献:
    名称:
    [EN] 2-AMINOINDOLE COMPOUNDS AND METHODS FOR THE TREATMENT OF MALARIA
    [FR] COMPOSÉS 2-AMINOINDOLES ET MÉTHODES DE TRAITEMENT DE LA MALARIA
    摘要:
    公开号:
    WO2011053697A8
  • 作为产物:
    描述:
    3-溴-5-硝基-2-羟基吡啶 、 trimethoxonium tetrafluoroborate 以 二氯甲烷 为溶剂, 生成 3-溴-2-甲氧基-5-硝基吡啶
    参考文献:
    名称:
    Heteroaryl spiroethercycloalkyl tachykinin receptor antagonists
    摘要:
    本发明涉及由结构式I表示的某些新化合物:##STR1##或其药学上可接受的盐,其中R.sup.3、R.sup.6、R.sup.7、R.sup.8、R.sup.11、R.sup.12、R.sup.13、A、m、n和虚线在此处定义。本发明还涉及包含这些新化合物作为活性成分的药物配方,以及在治疗某些疾病中使用这些新化合物及其配方。本发明的化合物是催吐肽受体拮抗剂,可用于治疗炎症性疾病、疼痛或偏头痛、哮喘和呕吐。
    公开号:
    US05929094A1
点击查看最新优质反应信息

文献信息

  • [EN] TRIFLUOROMETHOXYLATION OF ARENES VIA INTRAMOLECULAR TRIFLUOROMETHOXY GROUP MIGRATION<br/>[FR] TRIFLUOROMÉTHOXYLATION D'ARÈNES VIA UNE MIGRATION INTRAMOLÉCULAIRE DU GROUPE TRIFLUOROMÉTHOXY
    申请人:UNIV NEW YORK STATE RES FOUND
    公开号:WO2016057931A1
    公开(公告)日:2016-04-14
    The present invention provides a process of producing a trifluoromethoxylated aryl or trifluoromethoxylated heteroaryl having the structure: (I), wherein A is an aryl or heteroaryl, each with or without subsutitution; and R1 is -H, -(alkyl), -(alkenyl), -(alkynyl), -(aryl), -(heteroaryl), - (alkylaryl), - (alkylheteroaryl), -NH-(alkyl), -N(alkyl)2, -NH-(alkenyl), -NH-(alkynyl) -NH-(aryl), -NH-(heteroaryl), -O-(alkyl), -O-(alkenyl), -O-(alkynyl), -O-(aryl), -O-(heteroaryl), -S-(alkyl), -S- (alkenyl), -S-(alkynyl), -S-(aryl), or -S-(heteroaryl), comprising: (a) reacting a compound having the structure: (II), with a trifluoromethylating agent in the presence of a base in a first suitable solvent under conditions to produce a compound having the structure: (III); and (b) maintaining the compound produced in step (a) in a second suitable solvent under conditions sufficient to produce the trifluoromethoxylated aryl or trifluormethoxylated heteroaryl having the structure: (I).
    本发明提供了一种生产具有结构式(I)的三氟甲氧基取代的芳基或三氟甲氧基取代的杂芳基的方法,其中A是芳基或杂芳基,每个芳基或杂芳基可以有或无取代基;R1是-H,-(烷基),-(烯基),-(炔基),-(芳基),-(杂芳基),-(烷基芳基),-(烷基杂芳基),-NH-(烷基),-N(烷基)2,-NH-(烯基),-NH-(炔基)-NH-(芳基),-NH-(杂芳基),-O-(烷基),-O-(烯基),-O-(炔基),-O-(芳基),-O-(杂芳基),-S-(烷基),-S-(烯基),-S-(炔基),-S-(芳基)或-S-(杂芳基),包括:(a)使具有结构式(II)的化合物与三氟甲基化剂在第一适宜溶剂中的碱的存在下反应,在适宜条件下生成具有结构式(III)的化合物;以及(b)将步骤(a)中产生的化合物维持在第二适宜溶剂中,在足以生成具有结构式(I)的三氟甲氧基取代的芳基或三氟甲氧基取代的杂芳基的条件下保持。
  • [EN] AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS, SALTS THEREOF, AND METHODS OF SYNTHESIS THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES SUBSTITUÉS PAR UNE AMINE, UTILISÉS COMME INHIBITEURS DE L'EHMT2, SELS DE CEUX-CI, ET LEURS MÉTHODES DE SYNTHÈSE
    申请人:EPIZYME INC
    公开号:WO2019079540A1
    公开(公告)日:2019-04-25
    The present disclosure relates to amine-substituted heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., cancer) by administering an amine-substituted heterocyclic heterocyclic compound disclosed herein or a pharmaceutical composition thereof to subjects in need thereof. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
    本公开涉及氨基取代的杂环化合物。本公开还涉及包含这些化合物的药物组合物,以及通过向需要治疗的受试者施用本公开的氨基取代杂环化合物或其药物组合物来治疗疾病(例如,癌症)的方法。本公开还涉及将这些化合物用于研究或其他非治疗目的。
  • Practical bromination of arylhydroxylamines with SOBr2 towards ortho-bromo-anilides
    作者:Yuanbo Du、Zhenguo Xi、Lirong Guo、Haifeng Lu、Lei Feng、Hongyin Gao
    DOI:10.1016/j.tetlet.2021.153074
    日期:2021.5
    thionyl bromide is demonstrated in this work. Mild reaction conditions and broad scope of substrates ranging from heterocyclic structures to pharmaceutics-potential motifs are used in the reactions of this paper. Efficient bromination of ortho CH bonds of the aryhydroxylamines has been achieved. Ortho-bromoanilide products were obtained in good to excellent yields, and model scaled-up reactions of this
    这项工作证明了一种从容易获得的芳羟胺和亚硫酰溴合成邻溴代苯胺的简便方法。在本文的反应中使用了温和的反应条件和从杂环结构到药物潜在基序的广泛底物范围。已经实现了对羟基胺的邻位C H键的有效溴化。以高至极好的收率获得了邻溴代苯胺产品,并且在这项工作中显示了这种合成方法的模型放大反应。
  • [EN] INHIBITORS OF PI3 KINASE AND / OR MTOR<br/>[FR] INHIBITEURS DE LA PI3 KINASE ET/OU DU MTOR
    申请人:AMGEN INC
    公开号:WO2010126895A1
    公开(公告)日:2010-11-04
    The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds, wherein the variables are as defined herein.
    本发明涉及式I的化合物或其药用可接受盐;使用这些化合物治疗疾病或症状的方法,如癌症;以及含有这些化合物的药物组合物,其中变量如本文所定义。
  • NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF
    申请人:FUJIFILM Corporation
    公开号:US20140309225A1
    公开(公告)日:2014-10-16
    The object of the present invention is to provide a compound and a pharmaceutical composition having excellent Syk inhibitory activity. According to the present invention, a nicotinamide derivative represented by the following formula (I) or a salt thereof is provided, wherein R 1 is a substituent represented by the following formula (II-1), (III-1), or (IV-1) (wherein R 3 , R 4 , R 5 , n, and X 1 have the same definitions as those described in the specification), and R 2 is a pyridyl, indazolyl, phenyl, pyrazolopyridyl, benzisoxazolyl, pyrimidinyl, or quinolyl group, each of which optionally has at least one substituent.
    本发明的目的是提供一种具有优异的Syk抑制活性的化合物和药物组合物。根据本发明,提供了由以下式(I)表示的烟酰胺衍生物或其盐, 其中 R 1 是由以下式(II-1)、(III-1)或(IV-1)表示的取代基 (其中R 3 、R 4 、R 5 、n和X 1 的定义与说明书中描述的相同),而R 2 是吡啶基、吲唑基、苯基、吡唑吡啶基、苯并异噁唑基、嘧啶基或喹啉基,每种基可选择地具有至少一个取代基。
查看更多